“Go no Go” in plasma fractionation in the world's emerging economies: Still a question asked 70 years after the COHN process was developed!

Burnouf, 2011, Recombinant plasma proteins, Vox Sang, 100, 68, 10.1111/j.1423-0410.2010.01384.x

Liras, 2013, Treatment for hemophilia: recombinant versus plasma-derived coagulation factors – controversy and debate forever? An ethical medical challenge?, Expert Rev Hematol, 6, 489, 10.1586/17474086.2013.834798

Shapiro, 2013, Long-lasting recombinant factor VIII proteins for hemophilia A, Hematology Am Soc Hematol Educ Program, 2013, 37, 10.1182/asheducation-2013.1.37

Burnouf, 2007, Modern plasma fractionation, Transfus Med Rev, 21, 101, 10.1016/j.tmrv.2006.11.001

Farrugia, 2009, Plasma fractionation issues, Biologicals, 37, 88, 10.1016/j.biologicals.2009.01.005

Ala, 2012, External financial aid to blood transfusion services in sub-Saharan Africa: a need for reflection, PLoS Med, 9, 10.1371/journal.pmed.1001309

Klein, 2013, Should blood be an essential medicine?, N Engl J Med, 368, 199, 10.1056/NEJMp1213134

Burnouf, 2006, Current strategies to prevent transmission of prions by human plasma derivatives, Transfus Clin Biol, 13, 320, 10.1016/j.tracli.2006.11.001

Germishuizen, 2014, Quantifying the thrombogenic potential of human plasma-derived immunoglobulin products, Biologicals, 42, 260, 10.1016/j.biologicals.2014.04.002

Anonymous, 2007, Recommendations for the production, control and regulation of human plasma for fractionation, WHO Tech Rep Ser, 942

Cheraghali, 2009, Plasma fractionation, a useful means to improve national transfusion system and blood safety: Iran experience, Haemophilia, 15, 487, 10.1111/j.1365-2516.2008.01936.x

Cheraghali, 2009, Economical impact of plasma fractionation project in Iran on affordability of plasma-derived medicines, Transfus Med, 19, 363, 10.1111/j.1365-3148.2009.00961.x

Boulahdid, 2014, Improvement of national blood safety profile: effect of contract fractionation of plasma in resource limited countries, the Moroccan experience, Haemophilia, 20, e359, 10.1111/hae.12482

Radosevich, 2010, Intravenous immunoglobulin G: trends in production methods, quality control and quality assurance, Vox Sang, 98, 12, 10.1111/j.1423-0410.2009.01226.x

Burnouf, 2014, New approaches for manufacturing plasma derivatives, ISBT Sci Ser, 9, 160, 10.1111/voxs.12099

Li, 1998, Design, synthesis, and application of a protein A mimetic, Nat Biotechnol, 16, 190, 10.1038/nbt0298-190

Lihme, 2010, A novel core fractionation process of human plasma by expanded bed adsorption chromatography, Anal Biochem, 399, 102, 10.1016/j.ab.2009.12.002

Evtushenko, 2005, Blood protein purification and simultaneous removal of nonenveloped viruses using tangential-flow preparative electrophoresis, Electrophoresis, 26, 28, 10.1002/elps.200406150

El-Ekiaby, 2010, Solvent-detergent filtered (S/D-F) fresh frozen plasma and cryoprecipitate minipools prepared in a newly designed integral disposable processing bag system, Transfus Med, 20, 48, 10.1111/j.1365-3148.2009.00963.x

El-Ekiaby M., Radosevich M., Goubran H., El Sayed M., Burnouf T. Isbt. New methods of plasma fractionation – a presentation of the ‘mini-pool’ fractionation procedure developed in Egypt. Isbt Science Series, Vol 4, No 1, State of the Art Presentations 2009. p. 99–106.

Vargas, 2012, Purification of IgG and albumin from human plasma by aqueous two phase system fractionation, Biotechnol Prog, 28, 1005, 10.1002/btpr.1565

Blajchman, 2009, Protecting the blood supply from emerging pathogens: the role of pathogen inactivation, Transfus Clin Biol, 16, 70, 10.1016/j.tracli.2009.04.004

Dodd, 2012, Emerging pathogens and their implications for the blood supply and transfusion transmitted infections, Br J Haematol, 159, 135, 10.1111/bjh.12031

Burnouf, 2000, Reducing the risk of infection from plasma products: specific preventative strategies, Blood Rev, 14, 94, 10.1054/blre.2000.0129

Jorquera, 2007, Safety procedures of coagulation factors, Haemophilia, 13, 41, 10.1111/j.1365-2516.2007.01578.x

Remington, 2004, Inactivation of West Nile virus, vaccinia virus and viral surrogates for relevant and emergent viral pathogens in plasma-derived products, Vox Sang, 87, 10, 10.1111/j.1423-0410.2004.00530.x

Kreil, 2004, West Nile virus: recent experience with the model virus approach, Dev Biol (Basel), 118, 101

Burnouf, 2003, Nanofiltration of plasma-derived biopharmaceutical products, Haemophilia, 9, 24, 10.1046/j.1365-2516.2003.00701.x